Neurobiology of Depression and Anxiety in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Depression and anxiety are common in Parkinson's disease (PD) and have important consequences on quality of life. These have long been recognized as frequent accompanying syndromes of PD, and several reports suggest that these are the causative process or risk factors that are present many years before the appearance of motor symptoms. The neurochemical changes in PD involving dopamine, norepinephrine, and serotonin might be related to the pathophysiology of depression and anxiety, but this is still not clear. Several studies showed that anxiety in PD patients occurs earlier than depression, during premotor phase, suggesting that there may be a link between the mechanisms that cause anxiety and PD. Whereas a recent study reported that PD patients with depression and anxiety were associated with different demographic and clinical features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Association of coffee and caffeine intake with the risk of Parkinson disease
Ross, G. W. (2000) · JAMA · doi:10.1001/jama.283.20.2674 · Cited by 778 · cited 1×
“It has been suggested in the general population study that these traits, as well as the low premorbid rates of coffee drinking and alcohol consumption, may reflect an underlying damage to the mesolimbic dopaminergic pathways among individuals predisposed to PD [4].”
BackgroundNon-recognition of depression and other non-motor symptoms in Parkinson's disease
Shulman, L. M., Taback, R. L., Rabinstein, A. A., & Weiner, W. J. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00015-3 · Cited by 695
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease
Pontone, G. M., Williams, J. R., Anderson, K. E., Chase, G., Goldstein, S. A., Grill, S., Hirsch, E. S., Lehmann, S., Little, J. T., Margolis, R. L., et al. (2009) · Movement Disorders · doi:10.1002/mds.22611 · Cited by 305 · cited 1×
“Anxiety is a common NMSs among patients with PD and has a reported prevalence of 25–49% [16, 35], which is much higher than what is seen in non-PD subjects.”
BackgroundLambert, G., Johansson, M., Ågren, H., & Friberg, P. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.787 · Cited by 303
Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study
O'Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira‐Moriyama, L., & Lees, A. J. (2008) · Movement Disorders · doi:10.1002/mds.21813 · Cited by 290 · cited 1×
“Twenty-one percent of patients presented with NMSs including pain, urinary dysfunction, depression, and anxiety [3].”
BackgroundAtomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255 · cited 2×
“In addition, Atomoxetine, treated patients showed decreased severity of anxiety compared with Placebo group [24].”
BackgroundBurn, D. J. (2002) · Movement Disorders · doi:10.1002/mds.10114 · Cited by 223 · cited 1×
“One potential explanation for this increased prevalence of depression is the damage that PD has on the dopaminergic, serotonergic, and noradrenergic systems [21].”
Background
Cited by
Current and projected future economic burden of Parkinson’s disease in the U.S.
Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P., et al. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0117-1 · Cited by 657
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Johnson, M. E., & Bobrovskaya, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 332
Anxiety in Parkinson's disease: identification and management
Chen, J. J., & Marsh, L. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613495723 · Cited by 161
A systematic review of impulse control disorders in Parkinson’s disease.
Callesen, M. B., Scheel-Krüger, J., Kringelbach, M. L., & Møller, A. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120165 · Cited by 130
“In PD, the role of serotonin is very important in relation to both ICDs and emotional disturbances associated with the disease, such as depression, apathy, and anxiety [10].”
Background
Metadata
- Authors
- Kano, O., Ikeda, K., Cridebring, D., Takazawa, T., Yoshii, Y., & Iwasaki, Y.
- Venue
- Parkinson's Disease
- Publisher
- Hindawi Limited
- Published
- 2011
- Volume
- 2011
- Pages
- 1-5
- ISSN
- 2042-0080 (ISSN-L)
- OpenAlex
- W2095127925
- Cited by
- 107
- References
- 9
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.